CD8A and neoplasm: For example, McDonnell et al. reported the standard-dose gemcitabine would enhance the tumor-associated antigens cross‐presentation efficacy of tumor‐resident dendritic cells to enable the reactivation capacity of tumor‐infiltrating CD8 + T cells [63].